Vascular protection: A novel nonangiogenic cardiovascular role for vascular endothelial growth factor

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 20, Issue 6, 2000, Pages 1512-1520

  Zachary, Ian ^a   Mathur, Anthony ^a   Yla Herttuala, Seppo ^b   Martin, John ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Angiogenesis; Atherosclerotic; Endothelium; Nitric oxide; Prostacyclin

Indexed keywords

COMPLEMENTARY DNA; VASCULOTROPIN;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD VESSEL; CELL SURVIVAL; CLINICAL TRIAL; DRUG MECHANISM; ENDOTHELIUM CELL; GENE TARGETING; GENE THERAPY; HEART MUSCLE ISCHEMIA; HUMAN; INTRACORONARY INFUSION; NONHUMAN; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PROTECTION; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

EID: 0034091587     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.20.6.1512     Document Type: Article

References (120)

1. Ferrara N. Vascular endothelial growth factor. Eur J Cancer. 1996;32A: 2413-2422.
2. Risau W. Mechanisms of angiogenesis. Nature. 1997;386:671-674.
3. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nat Med. 1995;1:27-31.
4. Pepper MS. Manipulating angiogenesis: from basic science to the bedside. Arterioscler Thromb Vasc Biol. 1997;17:605-619.
5. Isner JM, Losordo DW. Therapeutic angiogenesis for heart failure. Nat Med. 1999;5:491-492.
6. Hockel M, Schlenger K, Doctrow S, Kissel T, Vaupel P. Therapeutic angiogenesis. Arch Surg. 1993;128:423-429.
7. Simons M, Ware JA. Food for starving hearts. Nat Med. 1996;2: 519-520.
8. Servos S, Zachary I, Martin JF. VEGF modulates NO production: the basis of a cytoprotective effect? Cardiovasc Res. 1999;41:509-510. Editorial.
9. Asahara T, Bauters C, Pastore C, Kearney M, Rossow S, Bunting S, Ferrara N, Symes JF, Isner JM. Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery. Circulation. 1995;91: 2793-2801.
10. Asahara T, Chen D, Tsurumi Y, Kearney M, Rossow S, Passeri J, Symes JF, Isner JM. Accelerated restitution of endothelial integrity and endothelial dependent function after phVEGF165 gene transfer. Circulation. 1996;94:3291-3302.
11. Van Belle E, Tio FO, Couffinhal T, Maillard L, Passeri J, Isner JM. Stent endothelialization: time course, impact of local catheter delivery, feasibility of recombinant protein administration, and response to cytokine expedition. Circulation. 1997;95:438-448.
12. Van Belle E, Tio FO, Chen D, Maillard L, Kearney M, Isner JM. Passivation of metallic stents after arterial gene transfer of phVEGF165 inhibits thrombus formation and intimai thickening. J Am Coll Cardiol. 1997;29:1371-1379.
13. Takeshita S, Zheng LP, Brogi E, Kearney M, Pu LQ, Bunting S, Ferrara, N, Symes JF, Isner JM. Therapeutic angiogenesis: a single intra-arterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischaemic hind limb model. J Clin Invest. 1994;93:662-670.
14. Banai S, Jaklitsch MT, Shou M, Lazarous DF, Scheinowitz M, Biro S, Epstein SE, Unger EF. Angiogenic-induced enhancement of collateral blood flow to ischaemic myocardium by vascular endothelial growth factor in dogs. Circulation. 1994;89:2183-2189.
15. Pearlman JD, Hibberd MG, Chuang ML, Harada K, Lopez JJ, Gladstone SR, Friedman M, Sellke FW, Simons M. Magnetic resonance mapping demonstrates benefits of VEGF-induced myocardial angiogenesis. Nat Med. 1995;1:1085-1089.
16. Bauters C, Asahara T, Zheng LP, Takeshita S, Bunting S, Ferrara N, Symes JF, Isner JM. Recovery of disturbed endothelium-dependent flow in the collateral-perfused rabbit ischaemic hindlimb after administration of vascular endothelial growth factor. Circulation. 1995;91:2802-2809.
17. Bauters C, Asahara T, Zheng LP, Takeshita S, Bunting S, Ferrara N, Symes JF, Isner JM. Site-specific therapeutic angiogenesis after systemic administration of vascular endothelial growth factor. J Vasc Surg. 1995;21:314-324.
18. Walder CE, Errett CJ, Bunting S, Lindquist P, Ogez JR, Heinsohn HG, Ferrara N, Thomas GR. Vascular endothelial growth factor augments muscle blood flow and function in a rabbit model of chronic hindlimb ischaemia. J Cardiovasc Pharmacol. 1996;27:91-98.
19. Harada K, Friedman M, Lopez JJ, Wang SY, Li J, Prasad PV, Pearlman, JD, Edelman ER, Sellke FW, Simons M. Vascular endothelial growth factor administration in chronic myocardial ischaemia. Am J Physiol. 1996;270:H1791-H1802.
20. Hariawala MD, Horowitz JR, Esakof D, Sheriff DD, Walter DH, Keyt B, Isner JM, Symes JF. VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts. J Surg Res. 1996;63:77-82.
21. Lopez JJ, Laham RJ, Stamler A, Pearlman JD, Bunting S, Kaplan A, Carrozza JP, Sellke FW, Simons M. VEGF administration in chronic myocardial ischaemia in pigs. Cardiovasc Res. 1998;40:272-281.
22. Mack CA, Patel SR, Schwarz EA, Zanzonico P, Hahn RT, Ilercil A, Devereux RB, Goldsmith SJ, Christian TF, Sanborn TA, Kovesdi I, Hackett N, Isom OW, Crystal RG, Rosengart TK. Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart. J Thorac Cardiovasc Surg. 1998;115:168-176.
23. Rakue H, Nakajima H, Katoh T, Usui M, Amemiya T, Miyagi M, Hara T, Tamura K, Sasame A, Naito Y, Nagai Y, Ibukiyama C. Low-dose basic fibroblast growth factor and vascular endothelial growth factor for angiogenesis in canine acute hindlimb insufficiency. Jpn Circ J. 1998; 62:933-939.
24. Luo Z, Asahara T, Tsurumi Y, Isner JM, Symes JF. Reduction of vein graft intimal hyperplasia and preservation of endothelium-dependent relaxation by topical vascular endothelial growth factor. J Vasc Surg. 1998;27:167-173.
25. Isner JM, Schainfeld R, Blair R, Haley L, Asahara T, Rosenfeld K, Razvi S, Walsh K, Symes JF. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF 165 in patient with ischaemic limb. Lancet. 1996;348:370-374.
26. Baumgartner I, Pieczek A, Manor O, Blair R, Kearney M, Walsh K, Isner JM. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation. 1998;97:1114-1123.
27. Schumacher B, Pecher P, von Specht BU, Stegmann T. Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation. 1998;97:645-650.
28. Losordo DW, Vale PR, Symes JF, Dunnington CH, Maysky M, Ashare AB, Lathi K, Isner JM. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as a sole therapy for myocardial ischemia. Circulation. 1998;98: 2800-2804.
29. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275:964-967.
30. Isner JM, Asahara T. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J Clin Invest. 1999;103: 1231-1236.
31. Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H, Inai Y, Silver M, Isner JM. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 1999;18:3964-3972.
32. Isner JM. Cancer and atherosclerosis: the broad mandate of angiogenesis. Circulation. 1999;99:1653-1655.
33. Geiringer E. Intimal vascularisation and atherosclerosis. J Pathol Bacteriol. 1951;63:201-211.
34. Kwon HM, Sangiorgi G, Ritman EL, McKenna C, Holmes DR Jr, Schwartz RS, Lerman A. Enhanced coronary vasa vasorum neovascularization in experimental hypercholesterolemia. J Clin Invest. 1998; 101:1551-1556.
35. Williams JK, Armstrong ML, Heistad DD. Vasa vasorum in atherosclerotic coronary arteries: responses to vasoactive stimuli and regression of atherosclerosis. Circ Res. 1988;62:515-523.
36. Moulton KS, Heller E, Konerding MA, Flynn E, Palinski W, Folkman J. Angiogenesis inhibitors endostatin or TNP-470 reduce intimai neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation. 1999;99:1726-1732.
37. Lazarous DF, Shou M, Scheinowitz M, Hodge E, Thirumurti V, Kitsiou AN, Stiber JA, Lobo AD, Hunsberger S, Guetta E, Epstein SE, Unger EF. Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury. Circulation. 1996;94:1074-1082.
38. Horrigan MC, MacIsaac AI, Nicolini FA, Vince DG, Lee P, Ellis SG, Topol EJ. Reduction in myocardial infarct size by basic fibroblast growth factor after temporary coronary occlusion in a canine model. Circulation. 1996;94:1927-1933.
39. Pepper MS, Ferrara N, Orci L, Montesano R. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun. 1992;189:824-831.
40. Asahara T, Bauters C, Zheng LP, Takeshita S, Bunting S, Ferrara N, Symes JF, Isner JM. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation. 1995;92(suppl II):II-365-II-371.
41. Ito WD, Arras M, Winkler B, Scholz D, Schaper J, Schaper W. Monocyte chemotactic protein-1 increases collateral and peripheral conductance after femoral artery occlusion. Circ Res. 1997;80:829-837.
42. Arras M, Ito WD, Scholz D, Winkler B, Schaper J, Schaper W. Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb. J Clin Invest. 1997;101:40-50.
43. Clauss M, Weich H, Breier G, Knies W, Rockl J, Waltenberger J, Risau W. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. J Biol Chem. 1996;271:17629-17634.
44. Lindahl P, Johansson BR, Leveen P, Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science. 1997; 277:242-245.
45. Henry TD, Annex BH, Azrin MA, McKendall GR, Willerson JT, Hendel RC, Giordano FJ, Klein R, Gibson CM, Berman DS, Luce CA, McCluskey ER. Double blind, placebo controlled trial of recombinant human vascular endothelial growth factor. J Am Coll Cardiol. 1999; 33:384A. Abstract.
46. Laitinen M, Hartikainen J, Eranen J, Kivinemi M, Hiltunen MO, Laakso M, Yla-Herttuala S. Catheter-mediated gene transfer to human coronary arteries after angioplasty: safety results from phase I Kuopio Angioplasty Gene Transfer Trial (KAT Trial). Circulation. 1998;98(suppl I):I-322. Abstract.
47. Laitinen M, Hartikainen J, Hiltunen MO, Eranen J, Kivinemi M, Narvenen O. Sylvan M, Martin JF, Laakso M, Yla-Herttuala S. Catheter mediated VEGF gene transfer to human coronary arteries after angioplasty. Hum Gen Ther. 2000;11:263-270.
48. Ku DD, Zaleski JK, Liu S, Brock TA. Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. Am J Physiol. 1993;265:H586-H592.
49. Horowitz JR, Rivard A, van der Zee R, Hariawala M, Sheriff DD, Esakof DD, Chaudhry GM, Symes JF, Isner JM. Vascular endothelial growth factor/vascular permeability factor produces nitric-oxide dependent hypotension. Arterioscler Thromb Vasc Biol. 1997;17: 2793-2799.
50. Clauss M, Gerlach M, Gerlach H, Brett J, Wang F, Familletti PC, Pan YC, Olander JV, Connolly DT, Stern D. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med. 1990;172:1535-1545.
51. Connolly DT, Olander JV, Heuvelman D, Nelson R, Monsell R, Siegel N, Haymore BL, Leimgruber R, Feder J. Human vascular permeability factor: isolation from U937 cells. J Biol Chem. 1989;264:20017-20024.
52. Booth RF, Martin JF, Honey AC, Hassall DG, Beesley JE, Moncada S. Rapid development of atherosclerotic lesions in the rabbit carotid artery induced by perivascular manipulation. Atherosclerosis. 1989;76: 257-268.
53. Soma MR, Donetti E, Parolini C, Mazzini G, Ferrari C, Fumagalli R, Paoletti R. HMG CoA reductase inhibitors: in vivo effects on carotid intimal thickening in normocholesterolemic rabbits. Arterioscler Thromb. 1993;13:571-578.
54. Laitinen M, Pakkanen T, Donetti E, Baetta R, Luoma J, Lehtolainen P, Viita H, Agrawal R, Miyanohara A, Friedmann T, Risau W, Martin JF, Soma M, Yla-Herttuala S. Gene transfer into the carotid artery using an adventitial collar: comparison of the effectiveness of the plasmid-liposome complexes, retroviruses, pseudotyped retroviruses, and adenoviruses. Hum Gene Ther. 1997;8:1645-1650.
55. Laitinen M, Zachary I, Breier G, Pakkanen T, Hakkinen T, Luoma J, Abedi H, Risau W, Soma M, Laakso M, Martin JF, Yla-Herttuala S. VEGF gene transfer reduces intimai thickening via increased production of nitric oxide in carotid arteries. Hum Gene Ther. 1997;8:1737-1744.
56. van der Zee R, Murohara T, Luo Z, Zollmann F, Passen J, Lekutat C, Isner JM. Vascular endothelial growth factor/vascular permeability factor augments nitric oxide release from quiescent rabbit and human vascular endothelium. Circulation. 1997;95:1030-1037.
57. Tsurumi Y, Murohara T, Krasinski K, Chen D, Witzenbichler B, Kearney M, Couffinhal T, Isner JM. Reciprocal relation between VEGF and NO in the regulation of endothelial integrity. Nat Med. 1997;3: 879-886.
58. 2 in endothelial cells via p42/p44 mitogen activated protein kinases. FEBS Letters. 1997;420:28-32.
59. Murohara T, Horowitz JR, Silver M, Tsurumi Y, Chen D, Sullivan A, Isner JM. Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation. 1998;97:99-107.
60. Criscuolo GR, Lelkes PI, Rotrosen D, Oldfield EH. Cytosolic calcium changes in endothelial cells induced by a protein product of human gliomas containing vascular permeability factor activity. J Neurosurg. 1989;71:884-891.
61. 2+-dependent pathway. Am J Physiol. 1997;273:H687-H694.
62. Garcia-Cardena G, Fan R, Shah V, Sorrentino R, Cirino G, Papapetropoulos A, Sessa WC. Dynamic activation of endothelial nitric oxide synthase by Hsp 90. Nature. 1998;392:821-824.
63. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest. 1989;83: 1774-1777.
64. Von der Leyen HE, Gibbons GH, Morishita R, Lewis NP, Zhang L, Nakajima M, Kaneda Y, Cooke JP, Dzau VJ. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci U S A. 1995;92:1137-1141.
65. Asada Y, Kisanuki A, Hatakeyama K, Takahama S, Koyama T, Kurozumi S, Sumiyoshi A. Inhibitory effects of prostacyclin analogue, TFC-132, on aortic neointimal thickening in vivo and smooth muscle cell proliferation in vitro. Prostaglandins Leukot Essent Fatty Acids. 1994;51:245-248.
66. 2+ mobilization, by cyclic AMP and GMP in rabbit aortic smooth muscle cells. Biochem J. 1992;288:527-532.
67. L'Allemain G, Lavoie JN, Rivard N, Baldin V, Pouyssegur J. Cyclin D1 expression is a major target of the cAMP-induced inhibition of cell cycle entry in fibroblasts. Oncogene. 1997;14:1981-1990.
68. Cospedal R, Lobo M, Zachary I. Differential regulation of extracellular signal-regulated kinases(ERK) 1 and 2 by cyclic AMP and dissociation of ERK inhibition from anti-mitogenic effects in rabbit vascular smooth muscle cells. Biochem J. 1999;342:407-414.
69. 2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomised placebo controlled trial. Br Heart J. 1994;71:7-15.
70. Barst RJ, Rubin LJ, Long WA, McGoon MD. Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension: the Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996;334:296-302.
71. Numaguchi Y, Naruse K, Harada M, Osani H, Mokuno S, Murase K, Matsui H, Toki Y, Ito T, Okumara K, Hayakawa T. Prostacyclin synthase gene transfer accelerates reendothelialization and inhibits neointimal formation in rat carotid arteries after balloon injury. Arterioscler Thromb Vasc Biol. 1999;19:727-733.
72. Varenne O, Pislaru S, Gillijns H, Van Pelt N, Gerard RD, Zoldhelyi P, Van de Werf F, Collen D, Janssens SP. Local adenovirus-mediated transfer of human endothelial nitric oxide synthase reduces luminal narrowing after coronary angioplasty in pigs. Circulation. 1998;98: 919-926.
73. 2), prostaglandin E1 and D2 on platelet aggregation in different species. Prostaglandins. 1978;16:373-388.
74. Schmidt HH, Walter U. NO at work. Cell. 1994;78:919-925.
75. Pepper MS, Ferrara N, Orci L, Montesano R. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Commun. 1991;181:902-906.
76. 2+ and von Willebrand factor release in human endothelial cells. Am J Pathol. 1991;138:213-221.
77. Ruggeri ZM, Ware J. von Willebrand factor. FASEB J. 1993;7:308-316.
78. Nemerson Y. Tissue factor and hemostasis. Blood. 1988;71:1-8.
79. Camera M, Giesen PL, Fallon J, Aufiero BM, Taubman M, Tremoli E, Nemerson Y. Cooperation between VEGF and TNF-alpha is necessary for exposure of active tissue factor on the surface of human endothelial cells. Anerioscler Thromb Vasc Biol. 1999;19:531-537.
80. Carmeliet P, Mackman N, Moons L, Luther T, Gressens P, Van Vlaenderen I, Demunck H, Kasper M, Breier G, Evrard P, Muller M, Risau W, Edgington T, Collen D. Role of tissue factor in embryonic blood vessel development. Nature. 1996;383:73-75.
81. Shoji M, Abe K, Nawroth PP, Rickles FR. Molecular mechanisms linking thrombosis and angiogenesis in cancer. Trends Cardiovasc Med. 1997;7:52-59.
82. Dejana E, Lampugnani MG, Giorgi M, Gaboli M, Federici AB, Ruggeri ZM, Marchisio PC. von Willebrand factor promotes endothelial cell adhesion via an Arg-Gly-Asp-dependent mechanism. J Cell Biol. 1989; 109:367-375.
83. Mohle R, Green D, Moore MA, Nachman RL, Rafii S. Constitutive production and thrombín-índuced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci U S A. 1997;94:663-668.
84. Wartiovaara U, Salven P, Mikkola H, Lassila R, Kaukonen J, Joukov V, Orpana A, Ristimaki A, Heikinheimo M, Joensuu H, Alitalo K, Palotie A. Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation. Thromb Haemost. 1998;80:171-175.
85. Weltermann A, Wolzt M, Petersmann K, Czerni C, Graselli U, Lechner K, Kyrle PA. Large amounts of vascular endothelial growth factor at the site of hemostatic plug formation in vivo. Arterioscler Thromb Vasc Biol. 1999;19:1757-1760.
86. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci U S A. 1991;88: 4651-4655.
87. DeCaterina R, Libby P, Peng HB, Thannickal VJ, Rajavashisth TB, Gimbrone MA Jr, Shin WS, Liao JK. Nitric oxide decreases cytokine-induced endothelial activation: nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest. 1995;96:60-68.
88. Bouloumié A, Schini-Kerth V, Busse R. Vascular endothelial growth factor up-regulates nitric oxide synthase expression in endothelial cells. Cardiovasc Res. 1999;41:773-780.
89. Hood JD, Meininger CJ, Ziehe M, Granger HJ. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol. 1998;274:H1054-H1058.
90. Alon T, Hemo I, Itin A, Pe'er J, Stone J, Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med. 1995;1: 1024-1028.
91. Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V, Ferrara N. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. J Biol Chem. 1998;273:30336-30343.
92. Thakker GD, Hajjar DP, Muller WA, Rosengart TK. The role of phosphatidylinositol 3′-kinase in vascular endothelial growth factor signaling. J Biol Chem. 1999;274:10002-10007.
93. Abedi H, Zachary I. Vascular endothelial growth factor stimulates tyrosine phosphorylation and recruitment to new focal adhesions of focal adhesion kinase and paxillin in endothelial cells. J Biol Chem. 1997;272:15442-15451.
94. Ilic D, Almeida EA, Schlaepfer DD, Dazin P, Aizawa S, Damsky CH. Extracellular matrix survival signals transduced by focal adhesion kinase suppress p53-mediated apoptosis. J Cell Biol. 1998;143:547-560.
95. Levkau B, Herren B, Koyama H, Ross R, Raines EW. Caspase-mediated cleavage of focal adhesion kinase pp125FAK and disassembly of focal adhesions in human endothelial cell apoptosis. J Exp Med. 1998;187: 579-586.
96. Frisch SM, Vuori K, Ruoslahti E, Chan-Hui PY. Control of adhesion-dependent cell survival by focal adhesion kinase. J Cell Biol. 1996;134: 793-799.
97. Van de Water B, Nagelkerke JF, Stevens JL. Dephosphorylation of focal adhesion kinase (FAK) and loss of focal contacts precede caspase-mediated cleavage of FAK during apoptosis in renal epithelial cells. J Biol Chem. 1999;274:13328-13337.
98. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin C. Different signal transduction properties of Kdr and Flt-1, two receptors for vascular endothelial growth factor. J Biol Chem. 1994;269: 26988-26995.
99. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999;13:9-22.
100. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell. 1998;92: 735-745.
101. Olofsson B, Pajusola K, Kaipainen A, von Euler G, Joukov V, Saksela O, Orpana A, Pettersson RF, Alitalo K, Eriksson U. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci U S A. 1996;93:2576-2581.
102. Jeltsch M, Kaipainen A, Joukov V, Meng X, Lakso M, Rauvala H, Swartz M, Fukumura D, Jain RK, Alitalo K. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science. 1997;276:1423-1425.
103. Achen MG, Jeltsch M, Kukk E, Makinen T, Vitali A, Wilks AF, Alitalo K, Stacker SA. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci U S A. 1998;95:548-553.
104. Witzenbichler B, Asahara T, Murohara T, Silver M, Spyridopoulos I, Magner M, Principe N, Kearney M, Hu JS, Isner JM. Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischaemia. Am J Pathol. 1998;153:381-394.
105. Stavri GT, Hong Y, Zachary IC, Breier G, Baskerville PA, Yla-Herttuala S, Risau W, Martin JF, Erusalimsky JD. Hypoxia and platelet-derived growth factor-BB synergistically upregulate the expression of vascular endothelial growth factor in vascular smooth muscle cells. FEBS Lett. 1995;358:311-315.
106. Stavri GT, Zachary IC, Baskerville PA, Martin JF, Erusalimsky JD. Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells. Circulation. 1995;92:5-8.
107. Brogi E, Wu T, Namiki A, Isner JM. Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only. Circulation. 1994;90:649-652.
108. Ramos MA, Kuzuya M, Esaki T, Miura S, Satake S, Asai T, Kanda S, Hayashi T, Iguchi A. Induction of macrophage VEGF in response to oxidized LDL and VEGF accumulation in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 1998;18:1188-1196.
109. Chen Y-X, Nakashima Y, Tanaka K, Shiraishi S, Nakagawa K, Sueishi K. Immunohistochemical expression of vascular endothelial growth factor/vascular permeability factor in atherosclerotic intimas of human coronary arteries. Arterioseler Thromb Vasc Biol. 1999;19:131-139.
110. Yla-Herttuala S. Vascular gene transfer. Curr Opin Lipidol. 1997;8: 72-76.
111. Noiri E, Hu Y, Bahou WF, Keese CR, Giaever I, Goligorsky MS. Permissive role of nitric oxide in endothelin-induced migration of endothelial cells. J Biol Chem. 1997;272:1747-1752.
112. Goligorsky MS, Abedi H, Noiri E, Takhtajan A, Lense S, Romanov V, Zachary I. Nitric oxide modulation of focal adhesions in endothelial cells. Am J Physiol. 1999;276:C1271-C1281.
113. Ziehe M, Morbidelli L, Choudhuri R, Zhang HT, Donnini S, Granger HJ, Bicknell R. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest. 1997;99:2625-2634.
114. Bauters C, Asahara T, Zheng LP, Takeshita S, Bunting S, Ferrara N, Symes JF, Isner JM. Physiological assessment of augmented vascularity induced by VEGF in ischemic rabbit hindlimb. Am J Physiol. 1994;267: H1263-H1271.
115. Takeshita S, Rossow ST, Kearney M, Zheng LP, Bauters C, Bunting S, Ferrara N, Symes JF, Isner JM. Time course of increased cellular proliferation in collateral arteries after administration of vascular endothelial growth factor in a rabbit model of lower limb vascular insufficiency. Am J Pathol. 1995;147:1649-1660.
116. Takeshita S, Pu LQ, Stein LA, Sniderman AD, Bunting S, Ferrara N, Isner JM, Symes JF. Intramuscular administration of vascular endothelial growth factor induces dose-dependent collateral artery augmentation in a rabbit model of chronic limb ischemia. Circulation. 1994;90(suppl II):II-228-II-234.
117. Hopkins SP, Bulgrin JP, Sims RL, Bowman B, Donovan DL, Schmidt SP. Controlled delivery of vascular endothelial growth factor promotes neovascularization and maintains limb function in a rabbit model of ischaemia. J Vasc Surg. 1998;27:886-894.
118. Takeshita S, Weir L, Chen D, Zheng LP, Riessen R, Bauters C, Symes, JF, Ferrara N, Isner JM. Therapeutic angiogenesis following arterial gene transfer of vascular endothelial growth factor in a rabbit model of hindlimb ischaemia. Biochem Biophys Res Commun. 1996;227: 628-635.
119. Takeshita S, Isshiki T, Ochiai M, Eto K, Mori H, Tanaka E, Umetani, K, Sato T. Endothelium-dependent relaxation of collateral microvessels after intramuscular gene transfer of vascular endothelial growth factor in a rat model of hindlimb ischemia. Circulation. 1998;98:1261-1263.
120. Isner JM, Baumgartner I, Rauh G, Schainfeld R, Blair R, Razvi S, Symes JF. Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results. J Vasc Surg. 1998;28:964-973.